BASKING RIDGE, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s top health insurers and the third largest Blue Cross Blue Shield affiliated company, has determined that non-implantable vagus nerve stimulation device, gammaCore, may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches. Highmark serves over 5 million patients across Pennsylvania, Delaware, and West Virginia.
"This coverage announcement marks a significant step forward. Highmark’s updated medical policy opens a new path to treatment access for many patients suffering from migraine and cluster headache,” said Frank Amato, chief executive officer of electroCore, Inc. “We look forward to this expanded coverage and will continue to work with providers, patients and doctors to build upon our mission of helping patients who are suffering from the debilitating effects of these disorders.”
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy FDA-cleared as an adjunctive therapy for the preventative treatment of cluster headache and as an acute treatment for pain associated with episodic cluster headache and migraine headache in adult patients. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers leading to a modulation of neurotransmitters and a reduction in pain.
gammaCore is the only therapy FDA cleared for the prevention of cluster headache.
gammaCore is available by prescription only and patients should speak with their doctor about whether gammaCore is right for them.
gammaCore™ (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for:
NOTE: This list is not all inclusive. Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
LifeSci Public Relations